RESUMEN
Microwave-induced thermoacoustic imaging (MTAI), combining the advantages of the high contrast of microwave imaging and the high resolution of ultrasonic imaging, is a potential candidate for breast tumor detection. MTAI probes have been used to extend thermoacoustic imaging to molecular imaging. However, due to the high content of water molecules in tissues, the thermoelastic expansion-based probes used in conventional MTAI are not capable of adequate enhancement. Herein, an MTAI nanoprobe for amplification of thermoacoustic (TA) signals by the stimulated liquid-gas phase transition mechanism has been developed, providing significantly higher signal amplitude than that from the conventional mechanism of thermoelastic expansion. The nanoprobe consists of liquid perfluorohexane (PFH) and tungsten disulfide (WS2) nanoparticles rich in defect electric dipoles. When irradiated with pulsed microwaves, the defect electric dipoles in WS2 were repeatedly polarized by gigahertz. This results in localized transient heating and an acoustic shockwave, which destroys the van der Waals forces between PFH molecules. Ultimately, liquid PFH droplets undergo a liquid-gas phase transition, generating dramatically enhanced TA signals. The practical feasibility was tested in vitro and in a breast tumor animal model. The results show that the proposed nanoprobe can greatly improve the contrast of tumor imaging. It will be a new generation probe for MTAI.
Asunto(s)
Imágenes de Microonda , Nanopartículas , Acústica , Animales , Diagnóstico por Imagen , MicroondasRESUMEN
It is difficult to keep the balance of high quality and high yield for graphene quantum dots (GQDs). Because the quality is uncontrollable during cutting large 2D nanosheets to small 0D nanodots by top-down methods and the yield is low for GQDs with high quality obtained from bottom-up strategy. Here, aphanitic graphite (AG), a low-cost graphite contains a large amount of small graphite nanocrystals with size of about 10 nm is used as the precursor of graphene oxide quantum dots (GO-QDs) for the first time. GO-QDs with high yield and high quality were successfully obtained directly by liquid phase exfoliating AG without high strength cutting. The yield of these GO-QDs can reach up to 40 wt. %, much higher than that obtained from flake graphite (FG) precursor (less than 10 wt. %). The size of GO-QDs can be controlled in 2-10 nm. The average thickness of GO-QDs is about 3 nm, less than 3 layer of graphene sheet. Graphene quantum dots (GQDs) with different surface properties can be easily obtained by simple hydrothermal treatment of GO-QDs, which can be used as highly efficient fluorescent probe. Developing AG as precursor for GQDs offers a way to produce GQDs in a low-cost, highly effective and scalable manner.
RESUMEN
Effective therapeutic strategies to precisely eradicate primary tumors with minimal side effects on normal tissue, inhibit metastases, and prevent tumor relapses, are the ultimate goals in the battle against cancer. We report a novel therapeutic strategy that combines adjuvant black phosphorus nanoparticle-based photoacoustic (PA) therapy with checkpoint-blockade immunotherapy. With the mitochondria targeting nanoparticle, PA therapy can achieve localized mechanical damage of mitochondria via PA cavitation and thus achieve precise eradication of the primary tumor. More importantly, PA therapy can generate tumor-associated antigens via the presence of the R848-containing nanoparticles as an adjuvant to promote strong antitumor immune responses. When combined with the checkpoint-blockade using anti-cytotoxic T-lymphocyte antigen-4, the generated immunological responses will further promote the infiltrating CD8 and CD4 T-cells to increase the CD8/Foxp3 T-cell ratio to inhibit the growth of distant tumors beyond the direct impact range of the PA therapy. Furthermore, the number of memory T cells detected in the spleen is increased, and these cells inhibit tumor recurrence. This proposed strategy offers precise eradication of the primary tumor and can induce long-term tumor-specific immunity. Electronic Supplementary Material: Supplementary material is available for this article at 10.1007/s12274-020-3028-x and is accessible for authorized users.